Study of nivolumab and chemo before surgery for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at real-world outcomes in Taiwan for people with resectable non-small cell lung cancer (NSCLC) who get nivolumab combined with chemotherapy before surgery. It aims to understand how well this treatment works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of lung cancer (NSCLC) that can be removed with surgery and has not spread to other organs.
- You must have received at least one cycle of nivolumab plus chemotherapy before surgery, starting on or after February 2023.
- You need a follow-up of at least 12 months after your first dose unless you passed away or had progression but kept visiting the doctor.
- Your lung cancer must be stage II or III (considered resectable by your doctor).
- You cannot have certain gene changes (EGFR or ALK) that are more common in some lung cancers, and you cannot have had any other cancer treatment for this lung cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
This study looks at how well the immunotherapy drug nivolumab (Opdivo) works when given with standard chemotherapy before surgery for people with a certain type of lung cancer that has not spread. It may help shrink the tumor before surgery.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This trial is testing a treatment given before surgery for non-small cell lung cancer. Patients receive chemotherapy plus immunotherapy (chemo-immunotherapy) first, then have surgery to remove the tumor. The goal is to see how well this approach works.
Hear when a new Non Small Cell Lung Cancer NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.